Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του galinos.gr από το 2011 μέχρι σήμερα
 

SPC, UK: LINEZOLID Film-coated tablets (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Linezolid 600 mg film-coated tablets.

Qualitative and quantitative composition

Each tablet contains 600 mg linezolid. For the full list of excipients, see section 6.1.

Pharmaceutical form

Film-coated tablet. White, ovaloid tablet debossed with LZD on one side and 600 on the other.

Therapeutic indications

Nosocomial pneumonia Community acquired pneumonia Linezolid is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible ...

Posology and method of administration

Posology Linezolid solution for infusion, film-coated tablets or oral suspension may be used as initial therapy. Patients who commence treatment on the parenteral formulation may be switched to either ...

Contraindications

Hypersensitivity to linezolid or to any of the excipients listed in section 6.1. Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, ...

Special warnings and precautions for use

Myelosuppression Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid ...

Interaction with other medicinal products and other forms of interaction

Monoamine oxidase inhibitors Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI). There are very limited data from drug interaction studies and on the safety of linezolid when ...

Fertility, pregnancy and lactation

Pregnancy There are limited data from the use of linezolid in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). A potential risk for humans exists. Linezolid should ...

Effects on ability to drive and use machines

Patients should be warned about the potential for dizziness or symptoms of visual impairment (as described in section 4.4 and 4.8) whilst receiving linezolid and should be advised not to drive or operate ...

Undesirable effects

The table below provides a listing of adverse drug reactions with frequency based on all-causality data from clinical studies that enrolled more than 2,000 adult patients who received the recommended linezolid ...

Overdose

No specific antidote is known. No cases of overdose have been reported. However, the following information may prove useful: Supportive care is advised together with maintenance of glomerular filtration. ...

Pharmacodynamic properties

Pharmacotherapeutic group: Other antibacterials ATC code: J01XX08 General properties Linezolid is a synthetic, antibacterial agent that belongs to a new class of antimicrobials, the oxazolidinones. It ...

Pharmacokinetic properties

Linezolid primarily contains (s)-linezolid which is biologically active and is metabolised to form inactive derivatives. Absorption Linezolid is rapidly and extensively absorbed following oral dosing. ...

Preclinical safety data

Linezolid decreased fertility and reproductive performance of male rats at exposure levels approximately equal to those in humans. In sexually mature animals these effects were reversible. However, these ...

List of excipients

Tablet core: Maize starch (corn derived) Microcrystalline cellulose (E460) Hydroxypropylcellulose (E463) Sodium starch glycollate type A Magnesium stearate (E572) Film coat: Opadry, white, YS-1-18202-A(e) ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 3 years.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

White, HDPE bottle with a polypropylene screw cap containing either 10*, 14*, 20*, 24, 30, 50 or 60 tablets. White, HDPE bottle with a polypropylene screw cap containing 100 tablets (for hospital use only). ...

Special precautions for disposal and other handling

No special requirements for disposal. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

Marketing authorization number(s)

PL 00057/1419

Date of first authorization / renewal of the authorization

Date of first authorisation: 23/11/2012 Date of last renewal: 22/02/2018

Date of revision of the text

02/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

File
application/pdf - 138,6 KB